A Phase 2 interventional study of RVU120 and Ruxolitinib in Advanced Solid Tumors, Acute Myeloid Leukaemia (AML) and High-risk Myelodysplastic Syndrome, sponsored by Ryvu Therapeutics SA. Enrolling by invitation at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Ryvu Therapeutics SA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Leukemia, Myeloid, Acute with a site in Poland — 14 open to participants now, 23 under way, 11 of them phase 3. Leukemia, Myeloid, Acute · Poland.
Among the 76 studies in Leukemia, Myeloid, Acute with a site in Poland, this one is the 73rd largest by planned enrollment of the 75 interventional ones that give a count, is one of 5 that started in 2025, is one of 17 in phase 2, reaches primary completion later than 4 of the 22 other live ones, and was the 74th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →14 of the 76 studies in Leukemia, Myeloid, Acute with a site in Poland are open now. Recruiting first, the newest first:
Syndax Pharmaceuticals · Sites in Poland, United States, Argentina and 20 more countries
Ages 12+
Kura Oncology, Inc. · Sites in Poland, United States, Australia and 14 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Poland, United States, Australia and 23 more countries
Ages 18+
Moleculin Biotech, Inc. · Sites in Poland, United States, Czechia and 6 more countries
Ages 18–80
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Sites in Poland, Germany, Italy and 4 more countries
Ages 6+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 30 · Phase 3 39 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 14 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 255 across the 75 interventional studies, 4,000 across the 1 observational. Of the 50 that completed or were terminated, 37 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
70 of 76 have an industry lead sponsor. The 10 most frequent:
Ryvu Therapeutics SA is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Ryvu Therapeutics SA has 4 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
8 of the studies in Leukemia, Myeloid, Acute with a site in Poland that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT06987058Ryvu Therapeutics SARVU120 Rollover Study | 2026-12 |
| NCT04953910Taiho Oncology, Inc.Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | 2026-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 76 studies in Leukemia, Myeloid, Acute with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when continued under the same regimen as in the parent study.
To be eligible for this rollover study, participants must be continuing to benefit from their treatment, show an acceptable safety profile, and not have access to commercially available comparator anticancer therapy. Once transitioned to this study, participants will continue with their next planned dose per the regimen of their parent study.
Participants may continue treatment until loss of clinical benefit as judged by the investigator, unacceptable toxicity, start of subsequent anticancer therapy, or until any other criterion for withdrawal from the treatment or the study is met.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study intervention is assigned in accordance with the parent protocol and consists of RVU120-based treatment.
Drug: RVU120
Drug: RVU120 · Drug: Ruxolitinib
Drug pages: SEL-120 · Romaciclib · Silevertinib
RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
Also known as: SEL120
Selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2
Incidence of Adverse Events (Safety and Tolerability)
Number and grade of adverse events assessed by CTCAE v5.0
Time frame: 12 months
Duration of response
Time from the first administration of RVU120-based treatment in the parent study until discontinuation of RVU120-based treatment for any reason in the rollover study.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's planned 12 months is below that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: SEL-120 · Romaciclib · Silevertinib
Ryvu Therapeutics SA